Marlon J. Hinner, Rachida-Siham Bel Aiba, Thomas Jaquin, Sven Berger, Manuela Dürr, Corinna Schlosser, Andrea Allersdorfer, Christine Rothe, Louis A. Matis, Shane A. Olwill Preclinical toxicology and pharmacology for the 4-1BB/HER2 bispecific PRS-343: A first-in-class costimulatory T cell engager
G. Matschiner, S. Huang, S. Constant, B. Rattenstetter, H. Gille, A.M. Hohlbaum, B.H. Koller, D. Keeling & M. Fitzgerald (2018) The Discovery and Development of AZD1402/PRS-060 a Potent and Selective Blocker of the IL-4 Receptor alpha
Lutz Renders, Ming Wen, Frank Dellanna, Sven Heinrichs, Klemens Budde, Christian Rosenberger, Christiane Erley,Birgit Bader, Claudia Sommerer, Schaier, Matthias, Werner Feuerer, Edgar Fenzl, Rachel van Swelm, Dorine Swinkels, Klaus Kutz, Louis Matis, Ulrich Moebius, Safety, tolerability, and pharmacodynamics of the hepcidin antagonist PRS-080#022-DP after single administration - a phase Ib study in anemic chronic kidney disease patients undergoing hemodialysis
Lutz Renders, Ming Wen, Frank Dellanna, Heinrichs, Sven, Klemens Budde, Christian Rosenberger, Christiane Erley, Birgit Bader, Claudia Sommerer, Schaier, Matthias, Werner Feuerer, Edgar Fenzl, Rachel van Swelm, Dorine Swinkels, Klaus Kutz, Louis Matis, Ulrich Moebius (2017) A phase Ib study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of the hepcidin antagonist PRS-080#022-DP in anemic chronic kidney disease patients undergoing hemodialysis
Hendrik Gille, Martin Hülsmeyer, Stefan Trentmann, Gabriele Matschiner, Hans Jürgen Christian, Todd Meyer, Ali Amirkhosravi, Laurent P. Audoly, Andreas M. Hohlbaum, Arne Skerra (2015) Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class
Marlon J. Hinner, Rachida-Siham Bel Aiba, Alexander Wiedenmann, Corinna Schlosser, Andrea Allersdorfer, Gabriele Matschiner, Christine Rothe, Ulrich Moebius, Shane A. Olwill (CRI 2015 Poster Presentation) Costimulatory T cell engagement via a novel bispecific anti-CD137/anti-HER2 protein based on Anticalin® technology
Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA (2014) In Vivo Visualization of MET Tumor Expression and Anticalin Biodistribution with the MET-Specific Anticalin 89Zr-PRS-110 PET Tracer
Gebauer M, Schiefner A, Matschiner G, Skerra A. (2013) Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin
Schönfeld, D., Matschiner, G., Chatwel,l L., Trentmann, S., Gille, H., Hülsmeyer, M., Brown, N., Kaye, P.M., Schlehuber, S., Hohlbaum, A.M., Skerra, A. (2009) An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. PNAS 19;106(20):8198-203.
Klaus Mross, Heike Richly, Richard Fischer, Dirk Scharr, Martin Büchert, Angelika Stern, Hendrik Gille, Laurent P. Audoly, Max E. Scheulen (2013) First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors
